CHOLINESTERASE INHIBITORS AND MEMANTINE FOR THE TREATMENT OF ALZHEIMER AND NON-ALZHEIMER DEMENTIAS

被引:22
作者
Balazs, Nora [1 ]
Bereczki, Daniel [1 ,2 ]
Kovacs, Tibor [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Neurol, Balassa U 6, H-1083 Budapest, Hungary
[2] MTA SE Neuroepidemiol Res Grp ELKH, Budapest, Hungary
来源
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE | 2021年 / 74卷 / 11-12期
关键词
dementia; therapy; treatment; cholinesterase inhibitors; memantine; ACETYLCHOLINESTERASE INHIBITORS; ANTIDEMENTIA DRUGS; DISEASE; ASSOCIATION; DIAGNOSIS; MODERATE; RIVASTIGMINE; MANAGEMENT; ATROPHY;
D O I
10.18071/isz.74.0379
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In aging societies, the morbidity and mortality of dementia is increasing at a significant rate, thereby imposing burden on healthcare, economy and the society as well. Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately two decades and over the years, more and more experience has been gained on their use in non-Alzheimer's dementias too. The aim of our work was to provide a comprehensive summary about the use of cholinesterase inhibitors and memantine for the treatment of Alzheimer's and non-Alzheimers's dementias.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 50 条
  • [41] Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
    Yanez, Matilde
    Vina, Dolores
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (14) : 1692 - 1706
  • [42] Pharmacoeconomics of Alzheimer’s disease (AD) treatment with cholinesterase inhibitors
    Jan Versijpt
    Acta Neurologica Belgica, 2012, 112 : 141 - 145
  • [43] Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea
    Ahn, So-Hyeon
    Choi, Nam-Kyong
    Kim, Ye-Jee
    Seong, Jong-Mi
    Shin, Ju-Young
    Jung, Sun-Young
    Park, Byung-Joo
    ARCHIVES OF PHARMACAL RESEARCH, 2015, 38 (06) : 1255 - 1262
  • [44] Cholinesterase inhibitors and memantine for symptomatic treatment of dementia
    Rodda, Joanne
    Carter, Janet
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [45] Test Your Memory (TYM test): diagnostic evaluation of patients with non-Alzheimer dementias
    Jeremy Brown
    Julie Wiggins
    Claire J. Lansdall
    Kate Dawson
    Timothy Rittman
    James B. Rowe
    Journal of Neurology, 2019, 266 : 2546 - 2553
  • [46] The controversial promises of cholinesterase inhibitors for Alzheimer's disease and related dementias: A qualitative study of caregivers' experiences
    Smith, Andre
    Kobayashi, Karen
    Chappell, Neena
    Hoxsey, Dann
    JOURNAL OF AGING STUDIES, 2011, 25 (04) : 397 - 406
  • [47] Non-Alzheimer's amnestic mild cognitive impairment with medial temporal hypometabolism
    De Keersmaecker, Sebastiaan
    De Meyer, Steffi
    Vandenberghe, Rik
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2024, 16 (04)
  • [48] Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer’s disease
    Linus Jönsson
    PharmacoEconomics, 2003, 21 : 1025 - 1037
  • [49] Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer's Disease
    Chioua, Mourad
    Perez, Marta
    Bautista-Aguilera, Oscar M.
    Yanez, Matilde
    Lopez, Manuela G.
    Romero, Alejandro
    Cacabelos, Ramon
    Puig de la Bellacasa, Raimon
    Brogi, Simone
    Butini, Stefania
    Borrell, Jose I.
    Marco-Contelles, Jose
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2015, 15 (08) : 648 - 658
  • [50] Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease in the Elderly
    Chad M. VanDen Berg
    Yusuf Kazmi
    Michael W. Jann
    Drugs & Aging, 2000, 16 : 123 - 138